Novo Nordisk (NVO - Get Report) ($168.98) plunged from $192.29 at the close on Feb. 8 to a low of $163.52 on Feb 11 after the U.S. Food and Drug Administration asked for additional testing on its diabetes treatments Tresiba and Ryzodeg. The stock is rated a buy with an overbought weekly chart profile and the five-week MMA at $175.94. My quarterly value level is $161.56 with a semiannual risky level at $176.21.
Nuance Communications (NUAN - Get Report) ($18.91) declined from $24.55 at the close on Feb. 7 to a low of $18.83 yesterday following an earnings miss. The stock is rated a buy with a negative weekly chart profile, the five-week MMA at $21.73 and the 200-week SMA at $19.18. My semiannual pivot is $20.75 with my annual risky level at $22.02.
Riverbed Technology (RVBD) ($16.12) declined from $20.10 at the close on Feb. 7 to a low of $15.92 on Feb 8 after missing Q4 earnings estimates. The stock is rated a hold with a negative weekly chart profile and the five-week MMA at $18.38. My quarterly value level is $15.42 with a monthly risky level at $21.81.
The Valspar (VAL) ($61.94) declined from $66.93 at the close on Feb. 11 to a low of $60.51 on Feb 12 after missing earnings estimates pre-market. The stock is rated a buy with an overbought weekly chart profile, and the five-week MMA at $64.63. My quarterly value level is $60.41 with a semiannual pivot at $63.37 and monthly risky level at $68.66.At the time of publication the author held no positions in any of the stocks mentioned. Follow @Suttmeier This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts